Genetically, this latter pathway is mostly driven by variants in TMEM106B and CHI3L1. Pathway-aware genetic studies with larger sample sizes and in more diverse ancestries are needed to further understand the complex etiology of AD and to translate genetic information to personalized medicine approaches. This evidence concerns the gene CHI3L1 and Alzheimer disease.